FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND: Form 990, tax year 2023
View the entire original 990 at ProPublica ↗
- Organization
- FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND (EIN 98-0407553)
- Tax period
- 2023-01-01 to 2023-12-31
- Filed
- 2024-11-15
- IRS object ID
- 202433209349311393
- Schema version
- 2023v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2024-11-15T11:33:25+00:00 | ReturnTs |
| Tax Period End | 2023-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 346565596 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ERNST & YOUNG US LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | ONE MANHATTAN WEST | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 100018604 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2023-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 980407553 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 0000000001 | PhoneNum |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | CHEMIN DU POMMIER 40 | AddressLine1Txt |
| City | GRANDSACONNEX | CityNm |
| Country | SZ | CountryCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DARRYL ENGLISH | PersonNm |
| Person Title | head of finance | PersonTitleTxt |
| Signature | 2024-11-15 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | Yucen Zhong | PreparerPersonNm |
| PTIN | P01593150 | PTIN |
| Phone | 2127733000 | PhoneNum |
| Preparation | 2024-11-15 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2023 | TaxYr |
| Build TS | 2024-10-15 13:58:12Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Change | Yes (X) | AddressChangeInd |
Doing Business As Name DoingBusinessAsName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | FIND | BusinessNameLine1Txt |
Principal Ofcr Business Name PrincipalOfcrBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | DAYO ADETIFA | BusinessNameLine1Txt |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | CHEMIN DU POMMIER 40 | AddressLine1Txt |
| City | GRANDSACONNEX | CityNm |
| Country | SZ | CountryCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $90,612,477 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.FINDDX.ORG | WebsiteAddressTxt |
| Type Of Organization Assoc | Yes (X) | TypeOfOrganizationAssocInd |
| Formation | 2003 | FormationYr |
| Legal Domicile Country | SZ | LegalDomicileCountryCd |
| Activity Or Mission | THE DEVELOPMENT AND IMPLEMENTATION OF NEW, LOW COST DIAGNOSTICS FOR INFECTIOUS DISEASES FOR USE IN LOW-RESOURCE AREAS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 8 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 8 | VotingMembersIndependentCnt |
| Total Employee | 147 | TotalEmployeeCnt |
| Total Volunteers | 8 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $142,991,509 | PYContributionsGrantsAmt |
| CY Contributions Grants | $86,961,801 | CYContributionsGrantsAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $961,319 | PYInvestmentIncomeAmt |
| CY Investment Income | $3,411,063 | CYInvestmentIncomeAmt |
| PY Other Revenue | $295,241 | PYOtherRevenueAmt |
| CY Other Revenue | $239,613 | CYOtherRevenueAmt |
| PY Total Revenue | $144,248,069 | PYTotalRevenueAmt |
| CY Total Revenue | $90,612,477 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $87,636,841 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $35,829,203 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $21,916,139 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $32,721,353 | CYSalariesCompEmpBnftPaidAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $1,244,315 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $36,633,518 | PYOtherExpensesAmt |
| CY Other Expenses | $27,566,683 | CYOtherExpensesAmt |
| PY Total Expenses | $146,186,498 | PYTotalExpensesAmt |
| CY Total Expenses | $96,117,239 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$1,938,429 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$5,504,762 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $137,542,319 | TotalAssetsBOYAmt |
| Total Assets EOY | $81,417,302 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $115,874,802 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $65,254,547 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $21,667,517 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $16,162,755 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $25,480,451 | ExpenseAmt |
| Grant | $13,087,039 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | See schedule O | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $17,309,907 | ExpenseAmt |
| Grant | $6,870,781 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | See schedule O | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $8,701,980 | ExpenseAmt |
| Grant | $2,948,582 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | See schedule O | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $30,536,891 | ExpenseAmt |
| Grant | $12,922,801 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | Antimicrobial Resistance (EXPENSES $5,623,858) AADAUC: Assessment AMR Dx and Abx in-country AMR CARBX Accelerator AMR Dx Accelerator AMR Molecular Assay AMR Neonatal Sepsis South Africa AMR Programme management AMR Score Card AMR STI WP2 Clinical Trial Site Development AMR Strategy AMR Surveillance digital toolkit - Kenya and Nepal COVID-19 Genomic surveillance CRP demonstration studies Cumulative Antibiograms EU ValueDx GoNoGo: Stewardship of new Gonorrhoea antibiotics HAMRAS: HAI surveillance and AMS Improve AMS practices at PHC: POC and digital NEOAMR: Neonatal Sepsis Diagnostic AMR Prevention Rapid Dual LFA for GN and CT Simplified Blood Culture WHO - FIND AMR In country WHO AMR Secondment Complex Humanitarian Environments (EXPENSES $273,112) Conflict Affected Settings Laboratory Strengthenin Partnership Building Hepatitis and HIV (EXPENSES $28,603) Global Policy HCV self-test Impact (EXPENSES $1,487,563) GAP Impact Network Impact general management Impact Information Foundational Value of Diagnostics Malaria and Fever (EXPENSES $3,638,444) Data from RDT lot-testing at time of procurement Dengue evaluation study Diagnosis for UHC Tracker Digital ETAT Evidence for non-invasive malaria tests Evidence Severity Field evaluation of a POC hematology platform FIND-GAVI collaboration FIND-GAVI collaboration (landscaping activities) FIND-GAVI collaboration (Meningo evaluations) G6PD biosensor implementation HS-RDT HRP2 impact studies Innovation Platform Malaria and Fever programme management Malaria specimen bank P. vivax malaria - serology tests POC hematology PvSTATEM: digital tool for PvSeroTAT Temperature stability Typhoid diagnostic Vital signs triage toolkit Medical Affairs (EXPENSES $3,342,484) Billing of specimen dstribution Biobanking Development Clinical Affairs general management Clinical Trial unit general management Clinical-Regulatory-QMS COVID-19 (CTU) Diagnostics center of excellence Medical Affairs general management Medical Affairs portfolio management Program coordination and supervision Regulatory unit general management Specimen bank unit general management Neglected Tropical Diseases (EXPENSES $5,142,868) BU LAMP BU RDT development Chagas disease RDT development CUIDA Chagas Evaluation of onchocerciasis diagnostics Evaluation of RDTs for chronic Chagas disease HAT (sleeping sickness) elimination HAT elimination (Angola) HAT elimination (Chad) HAT elimination (DRC) HAT elimination (Guinea) HAT elimination (South Sudan) HAT elimination (Uganda) HAT Kenya HAT RDT development NTD biobanking collection in Ghana NTD programme management Schistosomiasis CAA RDT development Visceral leishmaniasis Ag RDT development Visceral leishmaniasis elimination Non-Communicable Diseases (EXPENSES $1,975,355) ACCEDE: Access to CGMs for Equity in Diabetes Mgt Access to Cardiometabolic Management Access to Glucose Measurement Through DxConnect Diabetes Management Education Diabetes Quality Assurance Evidences Digital Education for Pharmacists - Mclinica HbA1c POC h2h Comparison NCD Programme Management New Tech for Diabetes & Cardiometabolic Conditions Pandemic Threats (EXPENSES $7,439,585) AgRDT Demonstration study in Botswana COVID-19 Eval Antigen RDTs COVID-19 external quality assessment molecular COVID-19 Mobile Labs COVID-19 Surveillance data digital tool-kit COVID-19 test and treat Diagnostic Network Optimization OB surveillance DXOD: Diagnostics for outbreak diseases Taskforce Evaluation of COVID-19 Molecular POC tests External Quality Assessment CV Antigen Testing G7-G20 Engagement Independent Evaluation of Ebola RDTs Marburg RDT product development OB Lassa Fever Response OB Lassa Fever Response-Dissemination and training OB preparedness and response in West Africa Pandemic Threats programme management PATH/WHO/FIND COVID-19 diagnostic benchmarking PT market assessment and landscape Test evaluation network for OB disease diagnostics Yellow Fever RDT R&D and Evaluation Surveillance (EXPENSES $265,435) Community-led outbreak Prep and response Surveillance general management Women's Health (EXPENSES $1,319,584) Cervical Cancer Elimination Cervical Cancer Elimination (Access) Cervical Cancer Elimination (Community) Cervical Cancer Elimination (Digital) Cervical Cancer Elimination (R&D Evaluation) Cervical Cancer Elimination (R&D Regulatory) HPV Cervical Cancer screening in Viet Nam WH programme management | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $30,536,891 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $12,922,801 | TotalOtherProgSrvcGrantAmt |
| Total Program Service Expenses | $82,029,229 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | false | LobbyingActivitiesInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | false | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | false | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | false | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | false | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | false | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (true) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (true) | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | Yes (true) | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | false | ProfessionalFundraisingInd |
| Fundraising Activities | false | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | false | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | false | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | false | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | false | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (true) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (true) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 0 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 147 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (true) | ForeignFinancialAccountInd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | false | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | false | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | false | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 8 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 8 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | false | MembersOrStockholdersInd |
| Election Of Board Members | false | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | false | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Form990 Provided To Gvrn Body | false | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| Own Website | Yes (X) | OwnWebsiteInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Sabri Ait-Kheira | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 0000000001 | PhoneNum |
Foreign Address ForeignAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | CHEMIN DU POMMIER 40 | AddressLine1Txt |
| City | GRANDSACONNEX | CityNm |
| Country | SZ | CountryCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (28 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| AYOADE ALAKIJA | |||||||||
| CHAIRMAN OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| CARLOS MOREL MEDICIS | |||||||||
| MEMBER OF THE BOARD (LEFT 11/23) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| DANIEL ROBERT CAMUS | |||||||||
| MEMBER OF THE BOARD (LEFT 11/23) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| DAVID HEYMANN | |||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| FRUTIGER CHRISTIAN | |||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| IONA KICKBUSH | |||||||||
| MEMBER OF THE BOARD (LEFT 11/23) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| KAMINENI SHOBANA | |||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| MARCEL TANNER | |||||||||
| MEMBER OF THE BOARD (LEFT 6/23) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| MICHELE COSTAFORLAZ | |||||||||
| MEMBER OF THE BOARD (JOINED 3/23) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| PRECIOUS MATSOSO | |||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| RICK ARTHUR BRIGHT | |||||||||
| MEMBER OF THE BOARD (JOINED 3/23) | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| SOUMYA SWAMINATHAN | |||||||||
| MEMBER OF THE BOARD | 1.0 | 0.0 | Yes (X) | $0 | $0 | $0 | |||
| CASSANDRA KELLY-CIRINO | |||||||||
| VP, HEALTH PROGRAMMES | 40.0 | 0.0 | $266,651 | $0 | $66,966 | Yes (X) | |||
| EMMA JANE HANNAY | |||||||||
| CHIEF ACCESS OFFICER | 40.0 | 0.0 | $247,968 | $0 | $53,498 | Yes (X) | |||
| LOUISA CHAUBERT | |||||||||
| DIRECTOR OF FINANCE | 40.0 | 0.0 | $267,747 | $0 | $62,926 | Yes (X) | |||
| MARTA FERNANDEZ SUAREZ | |||||||||
| CHIEF TECHNOLOGY OFFICER | 40.0 | 0.0 | $329,322 | $0 | $84,426 | Yes (X) | |||
| NORMA TORRES | |||||||||
| CHIEF OPERATING OFFICER | 40.0 | 0.0 | $145,082 | $0 | $16,250 | Yes (X) | |||
| SERGIO CARMONA | |||||||||
| CHIEF MEDICAL OFFICER | 40.0 | 0.0 | $342,556 | $0 | $74,970 | Yes (X) | |||
| SHARON SAACKS | |||||||||
| SENIOR DIRECTOR, PROGRAMME OPERATIONS | 40.0 | 0.0 | $252,163 | $0 | $63,150 | Yes (X) | |||
| WILLIAM RODRIGUEZ | |||||||||
| CHIEF EXECUTIVE OFFICER | 40.0 | 0.0 | $397,275 | $0 | $100,961 | Yes (X) | |||
| WILLO BROCK | |||||||||
| EXECUTIVE VP, EXTERNAL AFFAIRS | 40.0 | 0.0 | $320,525 | $0 | $0 | Yes (X) | |||
| DANIEL BAUSCH | |||||||||
| SNR. ADVISOR CEO; GLOBAL HEALTH SEC (LEFT 11/23) | 40.0 | 0.0 | $212,735 | $0 | $55,855 | Yes (X) | |||
| SANJAY SARIN | |||||||||
| VP, ACCESS | 40.0 | 0.0 | $238,003 | $0 | $0 | Yes (X) | |||
| BEATRICE MOUTON | |||||||||
| DIRECTOR, HUMAN RESOURCES | 40.0 | 0.0 | $246,488 | $0 | $54,956 | Yes (X) | |||
| BROOKE NICHOLS | |||||||||
| SENIOR DIRECTOR, IMPACT | 40.0 | 0.0 | $254,026 | $0 | $30,113 | Yes (X) | |||
| MORTEN RUHWALD | |||||||||
| DIRECTOR, TUBERCULOSIS PROGRAMME | 40.0 | 0.0 | $254,024 | $0 | $55,870 | Yes (X) | |||
| STEFANO ONGARELLO | |||||||||
| DIRECTOR, DATA SCIENCE | 40.0 | 0.0 | $230,390 | $0 | $54,167 | Yes (X) | |||
| SYLVAIN BIELER | |||||||||
| PRINCIPAL SCIENTIST | 40.0 | 0.0 | $235,512 | $0 | $43,469 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,240,467 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $817,577 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 120 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | false | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line2ContractorAddress/ForeignAddress/AddressLine2Txt | Province Or StateContractorAddress/ForeignAddress/ProvinceOrStateNm | Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SD BIOSENSOR INC | |||||||||||
| 16 DEOGYEONG-DAERO 1556BEON-GIL | GYEONGGIDO | KS | 16690 | MOLECULAR R&D | $4,054,130 | ||||||
| BIONEER CORP | |||||||||||
| 8-11 MUNPYEONGSEO-RO | KS | 306220 | MOLECULAR R&D | $4,000,000 | DAEDEOK-GU | DAEJEON | |||||
| DIAGNOSTIC CONSULTING NETWORK INC | |||||||||||
| HIGH PERFORMANCE RAP ASSAYS | $1,199,096 | 3193 LIONSHEAD AVE | CARLSBAD | CA | 92010 | ||||||
| XIXIA PHARMACEUTICALS | |||||||||||
| 123 TONETTI ST | HALFWAY HOUSE | SF | 1685 | LOCAL MANUFACTURING CAPACITY | $1,000,000 | MIDRAND | |||||
| AFRICAN SOCIETY FOR LABORATORY MEDICINE (ASLM) | |||||||||||
| THE PIVOT BLOCK E THIRD FLOOR | FOURWAYS | SF | LOCAL SYSTEMS STRENGTHENING | $979,800 | MONTECASINO BOULEVARD | GAUTENG | |||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 156 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $65,119,048 | GovernmentGrantsAmt |
| All Other Contributions | $21,842,753 | AllOtherContributionsAmt |
| Total Contributions | $86,961,801 | TotalContributionsAmt |
Total Oth Program Service Rev TotalOthProgramServiceRevGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $0 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $3,411,063 | TotalRevenueColumnAmt |
| Exclusion | $3,411,063 | ExclusionAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
| Personal | $0 | PersonalAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $0 | SecuritiesAmt |
| Other | $0 | OtherAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | commission on tax deduction | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $239,613 | TotalRevenueColumnAmt |
| Exclusion | $239,613 | ExclusionAmt |
Miscellaneous Revenue MiscellaneousRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $0 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $0 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $239,613 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $90,612,477 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $3,650,676 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,506,497 | TotalAmt |
| Program Services | $5,506,497 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $30,322,706 | TotalAmt |
| Program Services | $30,322,706 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,368,660 | TotalAmt |
| Program Services | $1,835,073 | ProgramServicesAmt |
| Management And General | $487,267 | ManagementAndGeneralAmt |
| Fundraising | $46,320 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $26,390,174 | TotalAmt |
| Program Services | $20,445,823 | ProgramServicesAmt |
| Management And General | $5,122,334 | ManagementAndGeneralAmt |
| Fundraising | $822,017 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,555,787 | TotalAmt |
| Program Services | $1,213,349 | ProgramServicesAmt |
| Management And General | $323,819 | ManagementAndGeneralAmt |
| Fundraising | $18,619 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $557,973 | TotalAmt |
| Program Services | $303,366 | ProgramServicesAmt |
| Management And General | $245,530 | ManagementAndGeneralAmt |
| Fundraising | $9,077 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,848,759 | TotalAmt |
| Program Services | $1,382,786 | ProgramServicesAmt |
| Management And General | $437,196 | ManagementAndGeneralAmt |
| Fundraising | $28,777 | FundraisingAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $876,113 | TotalAmt |
| Program Services | $360,075 | ProgramServicesAmt |
| Management And General | $516,038 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $489,127 | TotalAmt |
| Program Services | $291,535 | ProgramServicesAmt |
| Management And General | $197,592 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $421,978 | TotalAmt |
| Program Services | $205,068 | ProgramServicesAmt |
| Management And General | $216,910 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $213 | TotalAmt |
| Program Services | $213 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $972,241 | TotalAmt |
| Program Services | $828,394 | ProgramServicesAmt |
| Management And General | $143,847 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,697,206 | TotalAmt |
| Program Services | $1,436,454 | ProgramServicesAmt |
| Management And General | $1,260,752 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,182,998 | TotalAmt |
| Program Services | $6,500 | ProgramServicesAmt |
| Management And General | $1,176,498 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,725,429 | TotalAmt |
| Program Services | $2,995,544 | ProgramServicesAmt |
| Management And General | $577,372 | ManagementAndGeneralAmt |
| Fundraising | $152,513 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $845,013 | TotalAmt |
| Program Services | $740,092 | ProgramServicesAmt |
| Management And General | $98,197 | ManagementAndGeneralAmt |
| Fundraising | $6,724 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $505,672 | TotalAmt |
| Program Services | $297,469 | ProgramServicesAmt |
| Management And General | $208,203 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| Project contractor | $12,695,340 | $12,050,460 | $484,741 | $160,139 |
| EQUIPMENT & SUPPLIES | $1,654,059 | $1,515,245 | $138,685 | $129 |
| foreign exchange losses | $1,108,721 | $1,108,721 | ||
| TRANSLATION & SPONSORSHIP | $392,573 | $292,580 | $99,993 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Program Services | $0 | ProgramServicesAmt |
| Management And General | $0 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $96,117,239 | TotalAmt |
| Program Services | $82,029,229 | ProgramServicesAmt |
| Management And General | $12,843,695 | ManagementAndGeneralAmt |
| Fundraising | $1,244,315 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $39,489,542 | BOYAmt |
| EOY | $13,290,319 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $81,401,662 | BOYAmt |
| EOY | $59,797,621 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,215,019 | BOYAmt |
| EOY | $6,220,098 | EOYAmt |
Receivables From Officers Etc ReceivablesFromOfficersEtcGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,166,796 | BOYAmt |
| EOY | $1,814,846 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $6,989 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $0 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $6,989 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Investments Program Related InvestmentsProgramRelatedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Intangible Assets IntangibleAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $269,300 | BOYAmt |
| EOY | $287,429 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $137,542,319 | BOYAmt |
| EOY | $81,417,302 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $19,116,387 | BOYAmt |
| EOY | $11,866,468 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $96,758,415 | BOYAmt |
| EOY | $53,388,079 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Escrow Account Liability EscrowAccountLiabilityGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Loans From Officers Directors LoansFromOfficersDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $115,874,802 | BOYAmt |
| EOY | $65,254,547 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,607,693 | BOYAmt |
| EOY | $10,660,263 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,059,824 | BOYAmt |
| EOY | $5,502,492 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $21,667,517 | BOYAmt |
| EOY | $16,162,755 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $137,542,319 | BOYAmt |
| EOY | $81,417,302 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$5,504,762 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consol And Sep Basis Fincl Stmt | Yes (X) | ConsolAndSepBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | false | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $55,842,142 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $97,561,319 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $108,984,293 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $142,991,509 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $86,961,801 | CurrentTaxYearAmt |
| Total | $492,341,064 | TotalAmt |
Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $55,842,142 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $97,561,319 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $108,984,293 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $142,991,509 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $86,961,801 | CurrentTaxYearAmt |
| Total | $492,341,064 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $31,318,521 | SubstantialContributorsTotAmt |
| Public Support Total170 | $461,022,543 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $314,122 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $189,810 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $624,209 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $961,319 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $3,411,063 | CurrentTaxYearAmt |
| Total | $5,500,523 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $585,117 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $461,449 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $423,638 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $295,241 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $239,613 | CurrentTaxYearAmt |
| Total | $2,005,058 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $499,846,645 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $0 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.9223 | PublicSupportCY170Pct |
| Public Support PY170 | 0.872 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Schedule A, Part II COLUMNS A-C | THE SUPPORT AMOUNTS REPORTED IN COLUMNS A THROUGH C ARE REPORTED ON A CONSOLIDATED BASIS. |
| Schedule A, Part II, Line 10 Other Income | DESCRIPTION - COMMISSION ON TAX DEDUCTION, COLUMN A - 585117.0, COLUMN B - 461449.0, COLUMN C - 423638.0, COLUMN D - 295241.0, COLUMN E - 239613.0, COLUMN F - 2005058.0; |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule D IRS990ScheduleD
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $6,989 | OtherCostOrOtherBasisAmt |
| Depreciation | $0 | DepreciationAmt |
| Book Value | $6,989 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $6,989 | TotalBookValueLandBuildingsAmt |
| Total Rev Etc Audited Fincl Stmt | $90,612,477 | TotalRevEtcAuditedFinclStmtAmt |
| Other Revenue | $0 | OtherRevenueAmt |
| Revenue Not Reported | $0 | RevenueNotReportedAmt |
| Revenue Subtotal | $90,612,477 | RevenueSubtotalAmt |
| Other Revenues Not Included | $0 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $0 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $90,612,477 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $96,117,239 | TotExpnsEtcAuditedFinclStmtAmt |
| Other Expenses Included | $0 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $0 | ExpensesNotReportedAmt |
| Expenses Subtotal | $96,117,239 | ExpensesSubtotalAmt |
| Other Expenses Not Included | $0 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $96,117,239 | TotalExpensesPerForm990Amt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (9 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| Sub-Saharan Africa | 1 | 8 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $18,609,385 |
| South Asia | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $4,501,457 |
| East Asia and the Pacific | 1 | 10 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $10,390,772 |
| Europe (Including Iceland and Greenland) | 1 | 134 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $48,717,494 |
| South America | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $1,471,240 |
| North America (Canada & Mexico only) | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $975,680 |
| Russia and Neighboring States | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $187,743 |
| Middle East and North Africa | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $316,586 |
| Central America and the Caribbean | 0 | 0 | Program Services | LABORATORY STRENGTHENING EVALUATION WORK | $15,825 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 3 | SubtotalOfficesCnt |
| Subtotal Employees | 152 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 3 | TotalOfficeCnt |
| Total Employee | 152 | TotalEmployeeCnt |
| Subtotal Spent | $85,186,182 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $85,186,182 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (8 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Description Of Non Cash AsstDescriptionOfNonCashAsstTxt | Valuation Method UsedValuationMethodUsedDesc |
|---|---|---|---|---|---|
| Sub-Saharan Africa | DIAGNOSTICS | $11,121,076 | ELEC FD TRAN | N/A | N/A |
| South Asia | DIAGNOSTICS | $1,048,475 | ELEC FD TRAN | N/A | N/A |
| East Asia and the Pacific | DIAGNOSTICS | $7,197,982 | ELEC FD TRAN | N/A | N/A |
| Europe (Including Iceland and Greenland) | DIAGNOSTICS | $9,384,896 | ELEC FD TRAN | N/A | N/A |
| South America | DIAGNOSTICS | $1,030,413 | ELEC FD TRAN | N/A | N/A |
| North America (Canada & Mexico only) | DIAGNOSTICS | $417,024 | ELEC FD TRAN | N/A | N/A |
| Russia and Neighboring States | DIAGNOSTICS | $69,192 | ELEC FD TRAN | N/A | N/A |
| Middle East and North Africa | DIAGNOSTICS | $53,648 | ELEC FD TRAN | N/A | N/A |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 18 | Total501c3OrgCnt |
| Total Other Org | 124 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds | CONTRACTS ARE GIVEN FOR RESEARCH AND DEVELOPMENT OF NEW TOOLS FOR THE DIAGNOSIS OF INFECTIOUS DISEASES. EXCEPT FOR THE INITIAL ADVANCE PAYMENTS, PAYMENTS ARE CONDITIONAL UPON ACHIEVEMENT OF MILESTONES OR DELIVERABLES THROUGH THE PERIOD OF THE CONTRACT AS EVIDENCED IN CONTRACTUALLY SPECIFIED REPORTS. IN ADDITION TO THE REGULAR REPORTS, PROGRAM MANAGERS MONITOR PROGRESS WITH REGULAR COMMUNICATIONS AND PHYSICAL AND VIRTUAL SITE VISITS. FINALLY, MOST MAJOR GRANTS ARE SUBJECT TO ANNUAL DONOR AUDITS WHICH ARE IN ADDITION TO THE STATUTORY AUDIT. |
| Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements | CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; RUSSIA AND NEIGHBORING STATES-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual |
| Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements | EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; RUSSIA AND NEIGHBORING STATES-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (20 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc |
|---|---|---|---|---|---|---|---|
| Audere | |||||||
| 1191 2nd Ave Ste 450 | Seattle | WA | 98101 | $49,234 | Develop and make available digital tools for lay users to promote proper performance of CV-19 antigen RDTs and reporting of the results (ST project) | ||
| Baylor College of Medicine | |||||||
| 1 Baylor Plaza BCM 203 | Houston | TX | 77030 | $548,709 | Driving Equitable Access to Testing in LMICs through Effective and Affordable Tests and Infrastructure. | 741613878 | 501(C)(3) |
| Biomeme | |||||||
| 1015 Chestnut St Suite 1401 | Philadelphia | PA | 19107 | $685,000 | Development of diagnotic tests | ||
| Boston Children's Hospital | |||||||
| 300 Longwood Avenue | Boston | MA | 02115 | $7,708 | Research agreement for cross-cutting diseases | 042774441 | 501(C)(3) |
| Boston University | |||||||
| 25 Buick Street 2nd floor | Boston | MA | 02115 | $159,966 | Sponsored Research | 042103547 | 501(C)(3) |
| Broad Institute | |||||||
| 415 Main Street | Cambridge | MA | 02142 | $355,100 | Development of a rapide, point-of-care diagnostic for high sensitivity detection of Tuberculosis | 263428781 | 501(C)(3) |
| CHAI -Clinton Health Access Initiation Inc | |||||||
| 383 Dorchester Avenue suite 400 | Boston | MA | 02127 | $723,586 | To support TB elimination efforts | 271414646 | 501(C)(3) |
| Diagnostic Consulting Network Inc | |||||||
| 6354 Corte Del Abeto | Carlsbad | CA | 92011 | $1,012,297 | Development of diagnotic tests | 205531959 | |
| Dimagi Inc | |||||||
| 585 Massachusetts Avenue | Cambridge | MA | 02139 | $51,218 | Production of mobile phone apps that collects data from rapid vitro diagnostic test and that can aid an RDT user in interpreting the test results | 830343298 | |
| Elizabeth Glaser Pediatric Aids Foundation | |||||||
| 1140 Connecticut Ave NW Ste 200 | Washington | DC | 20036 | $206,993 | Evaluation of Antigen Rapid Diagnostic Tests. | ||
| Georgetown University | |||||||
| 3700 O St NW | Washington | DC | 20057 | $400,000 | Driving Equitable Access to Testing in LMICs through Effective and Affordable Tests and Infrastructure. | 530196603 | 501(C)(3) |
| Harvard College | |||||||
| 1350 Massachusetts Avenue Suite 72 | Cambridge | MA | 02138 | $39,206 | Project agreement with Harvard for Seq&Treat mutations catalogue work | 042103580 | 501(C)(3) |
| Meso Scale Diagnostics LLC | |||||||
| 1601 Research Boulevard | Rockville | MD | 20850 | $56,128 | Immunofluorescent TB LAM assay for TB diagnosis. | 521974952 | |
| Program Appropriate Tech in Health | |||||||
| 2201 Westlake Avenue Suite 200 | Seattlle | WA | 98121 | $206,912 | Genomics trainings. Supporting the Africa CDC Workforce Development Effort for Pathogen Genomic Surveillance | 911157127 | 501(C)(3) |
| Quantigen LLC | |||||||
| 10300 Kincaid Dr Suite 200 | Fishers | IN | 46037 | $22,491 | Accelerating tools to drive tuberculosis detection | ||
| The Regents of the University of California San Diego School of Medicine | |||||||
| 9500 Gilman Drive MC 0602 | La Jolla | CA | 920930602 | $338,978 | Consulting services and blood culture due diligence support | 956006144 | 501(C)(3) |
| University of North Carolina | |||||||
| 104 Airport Drive Suite 2200 | Chapel Hill | NC | 275991350 | $526,828 | Laboratory strengthening to support clinical care and research | 566001393 | 501(C)(3) |
| University of Alabama | |||||||
| 701 20th Street South AB 1170 | Birmingham | AL | 352940111 | $75,348 | Study to support clinical performance evaluation of Gonorrhoea | 636005396 | 501(C)(3) |
| University of Washington | |||||||
| 4333 Brooklyn Avenue NE Box 359472 | Seattle | WA | 98195 | $18,772 | Perform assessment of acceptability and usability of HCV self-testing among people who inject drugs in Kenya | 911486484 | 501(C)(3) |
| Wolf Greenfield and Sacks PC | |||||||
| 600 Atlantic Avenue | Boston | MA | 022102206 | $22,023 | IP landscape study directed to the detection of NGAL/LCN-2 biomarkers | ||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 12 | Total501c3OrgCnt |
| Total Other Org | 8 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. | FormAndLineReferenceDesc |
| Explanation | CONTRACTS ARE GIVEN FOR RESEARCH AND DEVELOPMENT OF NEW TOOLS FOR THE DIAGNOSIS OF INFECTIOUS DISEASES. EXCEPT FOR THE INITIAL ADVANCE PAYMENTS, PAYMENTS ARE CONDITIONAL UPON ACHIEVEMENT OF MILESTONES OR DELIVERABLES THROUGH THE PERIOD OF THE CONTRACT AS EVIDENCED IN CONTRACTUALLY SPECIFIED REPORTS. IN ADDITION TO THE REGULAR REPORTS, PROGRAM MANAGERS MONITOR PROGRESS WITH REGULAR COMMUNICATIONS AND PHYSICAL AND VIRTUAL SITE VISITS. FINALLY, MOST MAJOR GRANTS ARE SUBJECT TO ANNUAL DONOR AUDITS WHICH ARE IN ADDITION TO THE STATUTORY AUDIT. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | false | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | false | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | false | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (16 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WILLIAM RODRIGUEZ | ||||||||||||||
| CHIEF EXECUTIVE OFFICER | $364,452 | $0 | $32,823 | $0 | $0 | $0 | $77,558 | $0 | $23,403 | $0 | $498,236 | $0 | $0 | $0 |
| SERGIO CARMONA | ||||||||||||||
| CHIEF MEDICAL OFFICER | $336,733 | $0 | $5,823 | $0 | $0 | $0 | $68,319 | $0 | $6,651 | $0 | $417,526 | $0 | $0 | $0 |
| LOUISA CHAUBERT | ||||||||||||||
| DIRECTOR OF FINANCE | $263,260 | $0 | $4,487 | $0 | $0 | $0 | $57,399 | $0 | $5,527 | $0 | $330,673 | $0 | $0 | $0 |
| EMMA JANE HANNAY | ||||||||||||||
| CHIEF ACCESS OFFICER | $243,481 | $0 | $4,487 | $0 | $0 | $0 | $53,498 | $0 | $0 | $0 | $301,466 | $0 | $0 | $0 |
| WILLO BROCK | ||||||||||||||
| EXECUTIVE VP, EXTERNAL AFFAIRS | $314,168 | $0 | $6,357 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $320,525 | $0 | $0 | $0 |
| MARTA FERNANDEZ SUAREZ | ||||||||||||||
| CHIEF TECHNOLOGY OFFICER | $322,965 | $0 | $6,357 | $0 | $0 | $0 | $65,965 | $0 | $18,461 | $0 | $413,748 | $0 | $0 | $0 |
| SHARON SAACKS | ||||||||||||||
| SENIOR DIRECTOR, PROGRAMME OPERATIONS | $247,676 | $0 | $4,487 | $0 | $0 | $0 | $50,935 | $0 | $12,215 | $0 | $315,313 | $0 | $0 | $0 |
| CASSANDRA KELLY-CIRINO | ||||||||||||||
| VP, HEALTH PROGRAMMES | $260,828 | $0 | $5,823 | $0 | $0 | $0 | $53,954 | $0 | $13,012 | $0 | $333,617 | $0 | $0 | $0 |
| NORMA TORRES | ||||||||||||||
| CHIEF OPERATING OFFICER | $145,082 | $0 | $0 | $0 | $0 | $0 | $16,250 | $0 | $0 | $0 | $161,332 | $0 | $0 | $0 |
| DANIEL BAUSCH | ||||||||||||||
| SNR. ADVISOR CEO; GLOBAL HEALTH SEC (LEFT 11/23) | $208,248 | $0 | $4,487 | $0 | $0 | $0 | $45,062 | $0 | $10,793 | $0 | $268,590 | $0 | $0 | $0 |
| SANJAY SARIN | ||||||||||||||
| VP, ACCESS | $232,180 | $0 | $5,823 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $238,003 | $0 | $0 | $0 |
| MORTEN RUHWALD | ||||||||||||||
| DIRECTOR, TUBERCULOSIS PROGRAMME | $249,537 | $0 | $4,487 | $0 | $0 | $0 | $45,104 | $0 | $10,766 | $0 | $309,894 | $0 | $0 | $0 |
| BEATRICE MOUTON | ||||||||||||||
| DIRECTOR, HUMAN RESOURCES | $240,665 | $0 | $5,823 | $0 | $0 | $0 | $44,338 | $0 | $10,618 | $0 | $301,444 | $0 | $0 | $0 |
| STEFANO ONGARELLO | ||||||||||||||
| DIRECTOR, DATA SCIENCE | $225,903 | $0 | $4,487 | $0 | $0 | $0 | $43,739 | $0 | $10,428 | $0 | $284,557 | $0 | $0 | $0 |
| SYLVAIN BIELER | ||||||||||||||
| PRINCIPAL SCIENTIST | $231,025 | $0 | $4,487 | $0 | $0 | $0 | $43,469 | $0 | $0 | $0 | $278,981 | $0 | $0 | $0 |
| BROOKE NICHOLS | ||||||||||||||
| SENIOR DIRECTOR, IMPACT | $249,539 | $0 | $4,487 | $0 | $0 | $0 | $30,113 | $0 | $0 | $0 | $284,139 | $0 | $0 | $0 |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (14 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Form 990, Part III, Line 4a Technology & Development department | (EXPENSES $25,480,451 INCLUDING GRANTS OF $13,087,039)(REVENUE $0) In 2023, FIND made significant progress in projects aimed at improving global health through diagnostics. Achievements include advancements in true point-of-care diagnostic solutions, digital solutions, sequencing, and redistribution of manufacturing capacity over the works. One notable initiative was supporting the development of near-point-of-care and true point-of-care solutions for Covid-19. We collaborated with manufacturers on multi disease platforms and multiplex assays to decentralize diagnostics in LMICs, increasing access to quality testing in the least developed countries. In 2023, a significant project was undertaken to develop and evaluate methods for digitally-enabled integrated screening at the community level in Rwanda and Kenya. This initiative successfully demonstrated the feasibility of decentralizing community-level screening through digital tools, integrating disease screening into community-level digital platforms, and enhancing contact tracing modules for tuberculosis in Rwanda. Another significant achievement was leveraging data in all FIND's activities to become a data innovator in the diagnostics space. This involved making FIND a data-driven organization, implementing the DxConnect data portal to make diagnostics knowledge accessible globally, and integrating data governance into all business processes. This project induced a cultural shift within the organization, positioning FIND as a key player in global health data collaboratives. FIND also focused on transforming the diagnosis and treatment of drug-resistant TB (DR-TB) by accelerating the introduction and global adoption of targeted next-generation sequencing (NGS). Evidences generated by FIND through multi-country clinical evaluations of NGS solutions for the diagnosis of drug-resistant TB provided pivotal evidence for a WHO policy review and subsequently, WHO issued a rapid communication on the use of targeted NGS for the diagnosis of drug-resistant TB in July 2023. In the realm of COVID-19, FIND supported access to COVID-19 antigen rapid diagnostic tests (AgRDTs) in resource-limited countries. This involved partnerships with various manufacturers to develop, optimize, and evaluate high-quality AgRDTs, increase manufacturing capacity, and foster regional production through technology transfer. The project also focused on building regional manufacturing capacity for RDT tests, with an initial focus on HIV tests. FIND also aimed to develop low-cost self-tests and screening technologies to facilitate decentralized testing in healthcare facilities and at home. This initiative supported the registration of self-testing solutions in low- and middle-income countries (LMICs) and provided technology transfer and funding support to ensure rapid availability of these technologies. In addition to these projects, FIND's efforts in 2023 included the development of a yellow fever antigen rapid diagnostic test (RDT) and evidence generation for novel point-of-care (POC) molecular and antigen tests for mpox. These projects collectively contributed to advancing diagnostics, improving access to essential tests, and strengthening health systems in various regions. |
| Form 990, Part III, Line 4b Access department | (EXPENSES $17,309,907 INCLUDING GRANTS OF $6,870,781)(REVENUE $0) In 2023, FIND Access department executed several major initiatives across multiple regions. In Bihar, India, the LSS project provided technical assistance to strengthen laboratory systems, working closely with the government to implement IPHL guidelines and Essential Diagnosis List standards. Success hinged on strong government engagement and continuous on-site mentoring. The Essential Diagnostics Lists (EDL) program achieved significant progress in eight countries. FIND successfully supported NEDL development in Ethiopia, Gambia, Kenya, Malawi, and Vietnam, while work continues in Burkina Faso, Cameroun, and Sao Tome e Principe. In collaboration with ASLM, they published comprehensive guidance for NEDL development and implementation and evaluated factors influencing diagnostics selection and use in 55 African Union member states. FIND also collaborated with McGill University and the Bill & Melinda Gates Foundations Exemplars in Global Health team to generate evidence on exemplars in diagnostics and innovative solutions in diagnostics. This collaboration highlighted the best practices, fostered innovation, and set benchmarks for improving accuracy and efficiency in medical diagnostics. The Diagnostic Network Optimization (DNO) initiative expanded its impact through OptiDx, an advanced analytical tool designed to optimize diagnostic networks for TB, HIV, and other diseases in low and middle-income countries. This program has been particularly impactful in India, where implementation spans 52 districts across 10 states, focusing on universal DST scale-up and improved testing efficiency. FIND's DNO team also launched the DxGeoMap which is a user-friendly, online GIS application designed to map population accessibility to diagnostics with minimal data inputs. The DxGeoMap software helps users by estimating the potential impact of new diagnostic solutions and demonstrating the potential effectiveness of existing diagnostic system thus guiding how interventions may be strengthened. In Indonesia, FIND established a landmark partnership with the Ministry of Health, targeting the enhancement of 18,000 primary health centers. This comprehensive initiative encompasses essential diagnostics access, health workforce capacity building, pandemic surveillance improvement, and the advancement of local diagnostics manufacturing capabilities. The project also includes the development of Indonesia's first National Laboratory Strategic Plan. The ACTA Indo-Pacific Regional Project represents a collaborative effort across Cambodia, PNG, Laos PDR, and Indonesia. Working through a consortium of Australian institutes and CHAI, this initiative established the Regional Public Health Learning Network (RPHLN) and delivers tailored healthcare solutions in partnership with national governments. FIND made significant progress in accelerating Access to COVID-19 solutions by enhancing the accessibility and utilization of self-testing in LMICs. By evaluating commercially available self-tests and conducting comprehensive values and preferences surveys, FIND demonstrated that the public could effectively and satisfactorily use self-tests, which emerged as the preferred mode of testing. Market readiness evaluations were conducted to ensure that the self-tests were suitable for widespread use and could be effectively integrated into existing health systems. Evidence was generated and became crucial in supporting the development of WHO and national policies on self-testing, as well as in driving demand generation efforts to ensure broader adoption and implementation of self-testing practices. Through the objective of the COVID-19 ACTA Management R&D project, FIND has stimulated R&D to generate new innovative tests that enabled access to molecular testing at point of care. The project also monitored the COVID-19 test landscape, maintaining an up-to-date test directory that facilitated the introduction of new tests to the market and into country's testing algorithms. FIND has worked on enhancing access to COVID-19 testing in 4 priority countries (Nigeria, Kenya, the Democratic Republic of Congo (DRC), and Tanzania). These countries were selected due to their high estimated burdens of COVID-19 infection but low reporting rates. By engaging with local stakeholders to inform policy, building the capacity of community health workers and healthcare workers at primary health care (PHC) facilities, and promoting the use of antigen rapid diagnostic tests (RDTs) and self-tests, the project aimed to ensure widespread and effective testing. Additionally, the project supported the establishment of integrated pathways and the use of digital tools for screening and reporting, thereby strengthening the overall testing infrastructure and response in these countries. Collectively, all these projects demonstrated FIND's commitment to strengthening healthcare systems through improved diagnostics access, enhanced laboratory capabilities, and strategic partnerships with national governments and international organizations. |
| Form 990, Part III, Line 4c Tuberculosis (TB) programme | (EXPENSES $8,701,980 INCLUDING GRANTS OF $2,948,582)(REVENUE $0) To support policy for POC TB, MDR-TB tests and expanded TB testing in PLHIV, FIND conducted clinical evaluation of the impact of using the Molbio Truenat MTB platform/assays in the most peripheral level of healthcare. In addition, evaluated the Cepheid Xpert MTB/XDR 10-colour reflex assay for better diagnosis and quicker initiation of treatment for patients with different types of drug resistance. Also, ran clinical evaluation of an expanded TB diagnostic testing strategy for people living with HIV (PLHIV) using Ultra on sputum, stool and urine, and Abbott Determine TB LAM Ag test on urine, regardless of presence of TB symptoms. FIND's TPP project works in collaboration with WHO, provided a novel framework to guide the future development of TPPs for diagnostics, with an approach that balances accessibility and test performance for TB. FIND developed an impact model that considered access, cost and accuracy to guide performance targets. This work will yield new point-of-care (POC) tests for TB that provide results to the patient during the same clinical visit. This strongly supports the ongoing efforts to bring TB tests and results closer to patients, to enhance overall population-level health. To address the urgent need for a rapid biomarker-based, non-sputum-based test to detect all forms of TB for individuals of all ages, including children; FIND evaluated the Mycobacterium tuberculosis cell free DNA (Mtb-cfDNA) as a biomarker for TB detection. FIND study demonstrated improved analytical sensitivity of WATSON by targeting more loci, developed an improved primer design algorithm, and streamlined the protocol to minimize contamination, enable a more error-free workflow, and facilitate high-throughput evaluation of primers. FIND conducted performance evaluation of the Molbio Diagnostics Truenat MTB Plus/COVID-19 for TB and COVID-19 and NCD screening case detection using prospectively collected NP swabs and sputum samples from participants with symptoms suggestive of TB. The project was implemented in close collaboration with the boda-boda community, creating a high demand for community-based testing services. The digital tool captured complete data for more than 95% of participants and guided the selection of patients for TB and COVID 19 testing, including confirmatory PCR testing. The project allowed the piloting of integration models for other disease programmes, trained healthcare workers and other Ag RDT users, contributed to increased demand for testing, strengthened COVID-19 surveillance and infection prevention and control, and supported the management of Ag RDT supplies. The Unitaid-funded DriveDx4TB project aims to accelerate the introduction of TB diagnostics, after a thorough evaluation and review by internal and external experts, 11 products from 10 manufacturers were selected following an RFP and due diligence process, which was approved by Unitaid in April 2023. The completion of the values and preferences (V&P) study was a significant achievement for the year, assessing end-user preferences in South Africa, Viet Nam, and India for novel sample types, urine and tongue swabs. The study's findings provided essential insights into potential product reception and implementation considerations, with plans for further dissemination (including publications) expected in 2024. Additionally, FIND successfully developed a go-to-market framework including 6 consequential modules during the reporting period. To inform access terms and pricing, FIND initiated an independent cost of goods (COGs) analysis and willingness-to-pay analysis for the public and private sector buyers across all three product classes. Access terms and definitions were co-created by FIND and Unitaid and were included in the initial contracts sent to manufacturers; this process will be revisited during later stage-gates within the project. Lastly, DriveDx4TB actively participated in global and country-level advocacy efforts, including co-organizing a side-event at the UN high-level meeting on TB in New York. |
| Form 990, Part III, Line 4d Description of other program services | (Expenses $ 30,536,891 including grants of $ 12,922,801)(Revenue $ 0) Antimicrobial Resistance (EXPENSES $5,623,858) AADAUC: Assessment AMR Dx and Abx in-country AMR CARBX Accelerator AMR Dx Accelerator AMR Molecular Assay AMR Neonatal Sepsis South Africa AMR Programme management AMR Score Card AMR STI WP2 Clinical Trial Site Development AMR Strategy AMR Surveillance digital toolkit - Kenya and Nepal COVID-19 Genomic surveillance CRP demonstration studies Cumulative Antibiograms EU ValueDx GoNoGo: Stewardship of new Gonorrhoea antibiotics HAMRAS: HAI surveillance and AMS Improve AMS practices at PHC: POC and digital NEOAMR: Neonatal Sepsis Diagnostic AMR Prevention Rapid Dual LFA for GN and CT Simplified Blood Culture WHO - FIND AMR In country WHO AMR Secondment Complex Humanitarian Environments (EXPENSES $273,112) Conflict Affected Settings Laboratory Strengthenin Partnership Building Hepatitis and HIV (EXPENSES $28,603) Global Policy HCV self-test Impact (EXPENSES $1,487,563) GAP Impact Network Impact general management Impact Information Foundational Value of Diagnostics Malaria and Fever (EXPENSES $3,638,444) Data from RDT lot-testing at time of procurement Dengue evaluation study Diagnosis for UHC Tracker Digital ETAT Evidence for non-invasive malaria tests Evidence Severity Field evaluation of a POC hematology platform FIND-GAVI collaboration FIND-GAVI collaboration (landscaping activities) FIND-GAVI collaboration (Meningo evaluations) G6PD biosensor implementation HS-RDT HRP2 impact studies Innovation Platform Malaria and Fever programme management Malaria specimen bank P. vivax malaria - serology tests POC hematology PvSTATEM: digital tool for PvSeroTAT Temperature stability Typhoid diagnostic Vital signs triage toolkit Medical Affairs (EXPENSES $3,342,484) Billing of specimen dstribution Biobanking Development Clinical Affairs general management Clinical Trial unit general management Clinical-Regulatory-QMS COVID-19 (CTU) Diagnostics center of excellence Medical Affairs general management Medical Affairs portfolio management Program coordination and supervision Regulatory unit general management Specimen bank unit general management Neglected Tropical Diseases (EXPENSES $5,142,868) BU LAMP BU RDT development Chagas disease RDT development CUIDA Chagas Evaluation of onchocerciasis diagnostics Evaluation of RDTs for chronic Chagas disease HAT (sleeping sickness) elimination HAT elimination (Angola) HAT elimination (Chad) HAT elimination (DRC) HAT elimination (Guinea) HAT elimination (South Sudan) HAT elimination (Uganda) HAT Kenya HAT RDT development NTD biobanking collection in Ghana NTD programme management Schistosomiasis CAA RDT development Visceral leishmaniasis Ag RDT development Visceral leishmaniasis elimination Non-Communicable Diseases (EXPENSES $1,975,355) ACCEDE: Access to CGMs for Equity in Diabetes Mgt Access to Cardiometabolic Management Access to Glucose Measurement Through DxConnect Diabetes Management Education Diabetes Quality Assurance Evidences Digital Education for Pharmacists - Mclinica HbA1c POC h2h Comparison NCD Programme Management New Tech for Diabetes & Cardiometabolic Conditions Pandemic Threats (EXPENSES $7,439,585) AgRDT Demonstration study in Botswana COVID-19 Eval Antigen RDTs COVID-19 external quality assessment molecular COVID-19 Mobile Labs COVID-19 Surveillance data digital tool-kit COVID-19 test and treat Diagnostic Network Optimization OB surveillance DXOD: Diagnostics for outbreak diseases Taskforce Evaluation of COVID-19 Molecular POC tests External Quality Assessment CV Antigen Testing G7-G20 Engagement Independent Evaluation of Ebola RDTs Marburg RDT product development OB Lassa Fever Response OB Lassa Fever Response-Dissemination and training OB preparedness and response in West Africa Pandemic Threats programme management PATH/WHO/FIND COVID-19 diagnostic benchmarking PT market assessment and landscape Test evaluation network for OB disease diagnostics Yellow Fever RDT R&D and Evaluation Surveillance (EXPENSES $265,435) Community-led outbreak Prep and response Surveillance general management Women's Health (EXPENSES $1,319,584) Cervical Cancer Elimination Cervical Cancer Elimination (Access) Cervical Cancer Elimination (Community) Cervical Cancer Elimination (Digital) Cervical Cancer Elimination (R&D Evaluation) Cervical Cancer Elimination (R&D Regulatory) HPV Cervical Cancer screening in Viet Nam WH programme management |
| Form 990, Part V, Line 2a AND PART VII, SECTION A | INDIVIDUALS EMPLOYED BY FIND ARE NOT US RESIDENTS OR US EMPLOYEES. INFORMATION PERTAINING TO THE NUMBER OF EMPLOYEES AND EMPLOYEE COMPENSATION IS PROVIDED USING THE BEST INFORMATION AVAILABLE FROM EQUIVALENT W-2 & W-3 FORMS FOR THE VARIOUS COUNTRIES IN WHICH FIND EMPLOYS INDIVIDUALS. |
| Form 990, Part VI, Line 20 BOOKS IN CARE OF PHONE NUMBER | THE TELEPHONE NUMBER OF THE PERSON WHO POSSESSES THE BOOKS AND RECORDS IS +41 (22) 710 0590 |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM AND REVIEWED BY THE DIRECTOR OF FINANCE. ONCE APPROVED BY THE DIRECTOR OF FINANCE, THE FORM 990 IS ALSO REVIEWED BY THE CEO. ADDITIONALLY, IN 2021, FIND PARTICIPATED IN A BENCHMARKING EXERCISE WITH PEER OF FINANCE, THE FORM 990 IS ALSO REVIEWED BY THE CEO. ADDITIONALLY, IN 2021, FIND PARTICIPATED IN A BENCHMARKING EXERCISE WITH PEER ORGANIZATION TO ENSURE CONSISTENCY OF TREATMENT OF VARIOUS ITEMS ON FORM 990. |
| Form 990, Part VI, Line 12c Conflict of interest policy | FINDS CONFLICT OF INTEREST POLICY REQUIRES DIRECTORS, OFFICERS AND KEY EMPLOYEES, ALL OTHER STAFF MEMBERS, BOARD MEMBERS, CONSULTANTS AND PARTNERS TO DISCLOSE ACTUAL OR POTENTIAL CONFLICTS OF INTEREST WHEN THEY ARISE. THE PERSON OR COMPANY IS ALSO REQUIRED TO RECUSE THEMSELVES FROM ANY DECISION MAKING. |
| Form 990, Part VI, Line 15a Process to establish compensation of top management official | A REVIEW BY AN INDEPENDENT CONSULTANT OF THE CEO'S REMUNERATION PACKAGE WAS DONE BY THE BOARD AND FORMS THE BASIS OF A WRITTEN EMPLOYMENT CONTRACT. REMUNERATION TERMS FOR OFFICERS AND KEY EMPLOYEES ARE BASED ON MARKET RATES FOR SIMILAR POSITIONS IN SPECIFIC LOCATIONS. THE COMPENSATION COMMITTEE. THIS BENCHMARKING IS DONE AGAINST AN INDEPENDENT REPORT WHICH PRESENTS DATA COLLECTED FOR SIMILAR ORGANIZATIONS AND THIS EXERCISE IS DONE EVERY 3 YEARS. SALARIES FOR ALL STAFF ARE AVAILABLE TO THE BOARD AND COMPENSATION COMMITTEE. HOWEVER, THE SALARIES OF THE C-SUITE AND OTHER KEY STAFF ARE APPROVED BY THE COMPENSATION COMMITTEE. |
| Form 990, Part VI, Line 15b Process to establish compensation of other employees | A REVIEW BY AN INDEPENDENT CONSULTANT OF THE CEO'S REMUNERATION PACKAGE WAS DONE BY THE BOARD AND FORMS THE BASIS OF A WRITTEN EMPLOYMENT CONTRACT. REMUNERATION TERMS FOR OFFICERS AND KEY EMPLOYEES ARE BASED ON MARKET RATES FOR SIMILAR POSITIONS IN SPECIFIC LOCATIONS. THE COMPENSATION COMMITTEE. THIS BENCHMARKING IS DONE AGAINST AN INDEPENDENT REPORT WHICH PRESENTS DATA COLLECTED FOR SIMILAR ORGANIZATIONS AND THIS EXERCISE IS DONE EVERY 3 YEARS. SALARIES FOR ALL STAFF ARE AVAILABLE TO THE BOARD AND COMPENSATION COMMITTEE. HOWEVER, THE SALARIES OF THE C-SUITE AND OTHER KEY STAFF ARE APPROVED BY THE COMPENSATION COMMITTEE. |
| Form 990, Part VI, Line 19 Required documents available to the public | UPON REQUEST FIND'S GOVERNING DOCUMENTS (STATUTES AND BY-LAWS) CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE FOR INSPECTION AT FIND'S OFFICES IN GENEVA, SWITZERLAND. |
| Schedule F, Part I, Line 3(e) PROGRAM SERVICE DESCRIPTION | IN EACH REGION, FIND CONDUCTED THE FOLLOWING PROGRAM SERVICES - LABORATORY STRENGTHENING EVALUATION WORK. |
| Schedule F, Part II, Line 2 | DUE TO THE HIGH VOLUME OF ORGANIZATIONS THAT WERE PROVIDED ASSISTANCE FROM FIND DURING 2023, IT WOULD BE DIFFICULT FOR FIND TO LIST EACH ORGANIZATIONS AND GRANT AMOUNT INDIVIDUALLY ON SCHEDULE F, PART II. THEREFORE, FIND HAS LISTED THE TOTAL AMOUNT OF ASSISTANCE PROVIDED FOR REGION IN 2023. |
| FORM 990 Box E | THE ORGANIZATION'S TELEPHONE NUMBER IS +41 (22) 710 0590. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | Province Or StateForeignAddress/ProvinceOrStateNm | CountryForeignAddress/CountryCd |
|---|---|---|---|---|---|---|---|
| FIND INDIA | |||||||
| PROGRAM SERVICES | IN | FIND SWISS | Yes (true) | ||||
| FIND DX NPC | |||||||
| PROGRAM SERVICES | SF | FIND SWISS | Yes (true) | 89 ROODEBLOEM ROAD | WOODSTOCK | CAPE TOWN | SF |
| FIND DX KENYA | |||||||
| PROGRAM SERVICES | KE | FIND SWISS | Yes (true) | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | false | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | false | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | false | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | false | SharingOfFacilitiesInd |
| Paid Employees Sharing | false | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | false | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | false | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | Yes (true) | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (3 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| FIND DX KENYA | ||
| R | $1,257,956 | FMV |
| FIND DX NPC | ||
| R | $855,553 | FMV |
| FIND INDIA | ||
| R | $77,035 | FMV |